Evidence map›Paper›PMID 40841782›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Sustained-release of 4-hydroxytamoxifen inhibits capsular contracture after breast implant placement in a mouse model.

Nozomi Matsumoto, Masako Muguruma, Yoshiya Horimoto, Miki Okazaki, Mariko Asaoka, Takako Komiya, Eiichi Sato, Utako Yokoyama, Hajime Matsumura, Takashi Ishikawa

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nozomi MatsumotoDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan.
Masako MugurumaDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan.ORCID http://orcid.org/0009-0006-2269-0411
Yoshiya HorimotoDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan.ORCID http://orcid.org/0000-0001-8935-0768
Miki OkazakiDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan.
Mariko AsaokaDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan.
Takako KomiyaDepartment of Plastic and Reconstructive Surgery, Tokyo Medical University, Tokyo, Japan.
Eiichi SatoDepartment of Pathology (Medical Research Center), Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Utako YokoyamaDepartment of Physiology, Tokyo Medical University, Tokyo, Japan.
Hajime MatsumuraDepartment of Plastic and Reconstructive Surgery, Tokyo Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8788-7684
Takashi IshikawaDepartment of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo, 160-0023, Japan. tishik55@gmail.com.ORCID http://orcid.org/0000-0003-3450-4533

Funding

Japan Society for the Promotion of Science 22K09895
6 · The paper itself

Abstract

backgroundCapsular contracture is a major complication of breast reconstruction with silicone implants, affecting patients' quality of life due to pain and esthetic concerns. Capsular contracture is considered to result from an excessive fibrous foreign body reaction to the implant, but its precise mechanism remains unclear, and no effective preventative approaches have been established. Previously, we reported that transdermal application of 4-hydroxytamoxifen (4-OH TAM), an active metabolite of TAM, inhibited capsule formation in a mouse model. Building on this, we examined whether a sustained-release system, directly delivering 4-OH TAM around the silicone implant, could achieve a similar effect with clinical applications in mind.

methodsFifty-one female ICR mice were divided into three groups: non-treated control (NT), 0.1 mg 4-OH TAM (0.1mg_TAM), and 1.0 mg 4-OH TAM (1.0mg_TAM). A silicone implant was inserted subcutaneously on the back of each mouse, with a silk elastin sponge impregnated with 4-OH TAM placed on top as a sustained-release system. After four weeks, capsule formation was evaluated by measuring capsule thickness, fibrillar collagen density, and chronic inflammation (CD45R).

resultsThe 1.0mg_TAM group showed a significantly reduced capsule thickness compared to the NT group (p = 0.048). Although no statistical significance was observed, a decreasing trend was noted in fibrillar collagen density and CD45R-positive cell infiltration in the 1.0mg_TAM group (p = 0.175 and p = 0.260, respectively).

conclusionWe demonstrated that sustained-release administration of 4-OH TAM effectively suppresses capsule formation. Further investigations are required to explore its potential for clinical application.

Indexed as

Breast ImplantationBreast ImplantsImplant Capsular ContractureTamoxifenAnimalsDelayed-Action PreparationsDisease Models, AnimalFemaleHumansMiceMice, Inbred ICRafimoxifeneDelayed-Action PreparationsTamoxifenCapsular contractureCollagenDrug delivery systemsInflammationSilicone elastomersTamoxifen

Identifiers

PMID40841782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.